Compare CSTL & ADSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | ADSE |
|---|---|---|
| Founded | 2007 | 1980 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.7M | 577.8M |
| IPO Year | 2019 | N/A |
| Metric | CSTL | ADSE |
|---|---|---|
| Price | $39.29 | $12.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $42.83 | N/A |
| AVG Volume (30 Days) | ★ 370.2K | 18.9K |
| Earning Date | 11-03-2025 | 12-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $343,530,000.00 | $53,275,396.00 |
| Revenue This Year | $1.69 | $219.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.15 | N/A |
| 52 Week Low | $14.59 | $7.89 |
| 52 Week High | $42.18 | $16.35 |
| Indicator | CSTL | ADSE |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 56.60 |
| Support Level | $37.76 | $12.14 |
| Resistance Level | $42.18 | $12.62 |
| Average True Range (ATR) | 1.20 | 0.41 |
| MACD | -0.35 | -0.05 |
| Stochastic Oscillator | 46.17 | 76.22 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.